BIO

Bio-Rad Laboratories, Inc.Healthcare / Medical DevicesINTACT

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Share Price
$373.86
52W: $236.73 - $396.23
DCF Fair Value
$262.06
-42.7% Premium
P/E (TTM)
45.5x
ROIC
8.4%
Operating Margin
11.2%
FCF Yield
2.8%
Debt / Equity
0.19x
Piotroski Score
8/9
Altman Z-Score
3.49
Market Cap
$10B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($262.06)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)
()
Period Range
$ - $
DCF Fair Value
$262.06
MOS Buy Target (-25%)
$196.55
Valuation Overlays:

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price
$373.86
DCF Fair Value
$256.31
-45.9% Premium
$283M
$100M$283M (Reported)$50,000M
5.6%
-5%10% (Target)35%
4.5%
0%5%20%
9.0%
6%9% (Standard)15% (High Risk)
2.5%
1% (GDP Floor)2.5% (Inflation)4.0%
-$200M (Net Cash)
-$100B CashBalance Sheet+$150B Debt
10-Yr PV of Cash Flows
$2.4B
PV of Terminal Value
$3.1B
Implied Enterprise Value
$5.4B
Implied Equity Value
$5.6B
YearYr 1Yr 2Yr 3Yr 4Yr 5Yr 6Yr 7Yr 8Yr 9Yr 10
Projected FCF ($M)$299$316$333$352$372$388$406$424$443$463
Present Value (PV)$274$266$257$249$242$232$222$213$204$196

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-67.9% Premium
$222.62

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $8.21BVPS: $268.30
Revised Graham Formula-193.9% Premium
$127.19

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Buffett Owner Earnings3.3% Yield
$12.22 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.3BYield: 3.3%

Reverse DCF: Market Growth Expectation

FAIR BARRIER
10.6% CAGR (Next 10 Yrs)

At the current price of $373.86, the market is assuming the business will compound Free Cash Flow at 10.6% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict
ℹ Fair expectations: Requires steady execution.
Autonomous Thesis Underwriting

Surveil BIO with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Bio-Rad Laboratories, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 11.2% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Frequently Asked Questions: Bio-Rad Laboratories, Inc. (BIO) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Bio-Rad Laboratories, Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Bio-Rad Laboratories, Inc. has an estimated DCF intrinsic fair value of $262.06 per share compared to its current market price of $373.86. This represents an estimated 42.7% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $222.63.

Related Healthcare Value Stocks & Sector Peers

Compare Bio-Rad Laboratories, Inc. with audited intrinsic valuation models across the Healthcare sector.

View All S&P 500 Stocks